Patients who received ivonescimab and chemotherapy lived an average of 27.9 months, compared with 23.7 months for those who received Tevimbra and chemotherapy, according to a brief summary of the study results.
Sign up here.
The company had reported… [2303 chars]
Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial
